This article earned the "Dark Cloud" distinction. Yeesh.
pharmsamp now is "Dark Cloud" extinction. One of the normal trick of the shorts that he pulled. Continue to keep his post up at the top of the message board with the negative news and at the same time claim that I am long. Thanks for all the shorts that make the long earm money. pharmsamp claims that he is a hospital pharmacist. I doubted that a hospital pharmacist has much time to write up lot of garbage and post it up here. He is a "shortie". Period. Now, he disappear after the judge decision
We have seen them try everything in the last few weeks. They were bumping this crappy string past 7pm tonight. Good Luck to Longs and MNTA. For me this is five years and counting, but every year I increased my holdings.
My impression is that SNY may claim (or is claiming) that M-enoxaparin is biosimilar, and therefore, a new drug that should have been processed under the NDA. Meanwhile, the FDA's position, and by extension those of MNTA, Novartis/Sandoz, the AARP, and Medco is that it is a generic drug that was properly filed as an ANDA.
Since this is the first case of its kind I think we can cut the press and investors some slack as the technology is very, very complex and a single word that encompasses this new technology is necessary for simple minds like mine to grasp it.
That's my take as well.
Here's the best discussion that I've seen about the subject from a reputable source: